Ionis Pharmaceuticals IncNASDAQ:IONS
- LAST PRICE37.0700
- TODAY'S CHANGE (%)-2.1400 (-5.4578%)
- Bid / Lots37.0600/ 2
- Ask / Lots37.1000/ 1
- Open / Previous Close39.0000 / 39.2100
- Day Range
- 52 Week Range
- Volume1,918,800
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IONS |
|---|---|---|
| 09:32 ET | 86734 | 38.805 |
| 09:34 ET | 144325 | 38.35 |
| 09:36 ET | 24820 | 38.095 |
| 09:38 ET | 57777 | 38.03 |
| 09:39 ET | 8620 | 38.52 |
| 09:41 ET | 14888 | 38.165 |
| 09:43 ET | 2210 | 38.11 |
| 09:45 ET | 203316 | 38.22 |
| 09:48 ET | 15494 | 38.39 |
| 09:50 ET | 728 | 38.33 |
| 09:52 ET | 3298 | 37.92 |
| 09:54 ET | 9295 | 37.72 |
| 09:56 ET | 6334 | 37.97 |
| 09:57 ET | 500 | 37.955 |
| 09:59 ET | 6093 | 37.965 |
| 10:01 ET | 7902 | 37.88 |
| 10:03 ET | 7066 | 37.91 |
| 10:06 ET | 2881 | 37.86 |
| 10:08 ET | 31336 | 37.655 |
| 10:10 ET | 20399 | 37.59 |
| 10:12 ET | 3435 | 37.6 |
| 10:14 ET | 367944 | 37.625 |
| 10:15 ET | 1400 | 37.68 |
| 10:17 ET | 1100 | 37.65 |
| 10:19 ET | 15322 | 37.49 |
| 10:21 ET | 2028 | 37.56 |
| 10:24 ET | 4076 | 37.575 |
| 10:26 ET | 5163 | 37.52 |
| 10:28 ET | 2531 | 37.55 |
| 10:30 ET | 2718 | 37.49 |
| 10:32 ET | 3098 | 37.5 |
| 10:33 ET | 3040 | 37.48 |
| 10:35 ET | 11113 | 37.28 |
| 10:37 ET | 18391 | 37.27 |
| 10:39 ET | 33241 | 37.135 |
| 10:42 ET | 15285 | 36.94 |
| 10:44 ET | 8076 | 36.9 |
| 10:46 ET | 15621 | 36.87 |
| 10:48 ET | 32729 | 36.82 |
| 10:50 ET | 7529 | 36.845 |
| 10:51 ET | 7500 | 37.1824 |
| 10:53 ET | 4850 | 37.03 |
| 10:55 ET | 5243 | 36.9815 |
| 10:57 ET | 3719 | 37.04 |
| 11:00 ET | 5929 | 37.135 |
| 11:02 ET | 1625 | 37.1441 |
| 11:04 ET | 4823 | 37.035 |
| 11:06 ET | 2500 | 37.3 |
| 11:08 ET | 2025 | 37.29 |
| 11:09 ET | 4084 | 37.17 |
| 11:11 ET | 6979 | 37.23 |
| 11:13 ET | 2932 | 37.34 |
| 11:15 ET | 2361 | 37.3348 |
| 11:18 ET | 1396 | 37.34 |
| 11:20 ET | 5031 | 37.3 |
| 11:22 ET | 1020 | 37.315 |
| 11:24 ET | 5271 | 37.26 |
| 11:26 ET | 3774 | 37.22 |
| 11:27 ET | 2161 | 37.23 |
| 11:29 ET | 2497 | 37.22 |
| 11:31 ET | 1445 | 37.25 |
| 11:33 ET | 2765 | 37.22 |
| 11:36 ET | 8097 | 37.33 |
| 11:38 ET | 2318 | 37.4 |
| 11:40 ET | 2766 | 37.28 |
| 11:42 ET | 3048 | 37.28 |
| 11:44 ET | 2022 | 37.265 |
| 11:45 ET | 2389 | 37.24 |
| 11:47 ET | 2500 | 37.25 |
| 11:49 ET | 597 | 37.26 |
| 11:51 ET | 35185 | 37.48 |
| 11:54 ET | 5002 | 37.47 |
| 11:56 ET | 10006 | 37.475 |
| 11:58 ET | 7047 | 37.5 |
| 12:00 ET | 18448 | 37.52 |
| 12:02 ET | 1935 | 37.37 |
| 12:03 ET | 11361 | 37.33 |
| 12:05 ET | 5800 | 37.3 |
| 12:07 ET | 3091 | 37.174 |
| 12:09 ET | 1252 | 37.25 |
| 12:12 ET | 2490 | 37.26 |
| 12:14 ET | 1470 | 37.27 |
| 12:16 ET | 5513 | 37.27 |
| 12:18 ET | 1189 | 37.265 |
| 12:20 ET | 3020 | 37.3 |
| 12:21 ET | 421 | 37.305 |
| 12:23 ET | 8778 | 37.265 |
| 12:25 ET | 1665 | 37.3961 |
| 12:27 ET | 1308 | 37.38 |
| 12:30 ET | 400 | 37.35 |
| 12:32 ET | 100 | 37.39 |
| 12:34 ET | 500 | 37.375 |
| 12:36 ET | 11044 | 37.19 |
| 12:38 ET | 1053 | 37.25 |
| 12:39 ET | 1005 | 37.21 |
| 12:41 ET | 300 | 37.23 |
| 12:43 ET | 1228 | 37.25 |
| 12:45 ET | 2158 | 37.24 |
| 12:48 ET | 2052 | 37.215 |
| 12:50 ET | 1634 | 37.25 |
| 12:52 ET | 3615 | 37.26 |
| 12:54 ET | 4434 | 37.2 |
| 12:56 ET | 1423 | 37.25 |
| 12:57 ET | 1000 | 37.2 |
| 12:59 ET | 1038 | 37.25 |
| 01:01 ET | 2129 | 37.17 |
| 01:03 ET | 3360 | 37.09 |
| 01:06 ET | 1624 | 37.08 |
| 01:08 ET | 2249 | 37.13 |
| 01:10 ET | 500 | 37.06 |
| 01:12 ET | 3027 | 37.085 |
| 01:14 ET | 200 | 37.075 |
| 01:15 ET | 698 | 37.125 |
| 01:17 ET | 3544 | 37.145 |
| 01:19 ET | 2085 | 37.1138 |
| 01:21 ET | 600 | 37.11 |
| 01:24 ET | 500 | 37.07 |
Today
DJ Ionis to Fly Solo on Angelman Syndrome Drug -- Market Talk, from 1 hour ago by Dow Jones
1 hour ago by Dow JonesDJ Biogen, Ionis Terminate Development of BIIB105 for Amyotrophic Lateral Sclerosis, from 5 hours ago by Dow Jones
5 hours ago by Dow JonesIonis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis, from 6 hours ago by Dow Jones
6 hours ago by Dow JonesBiogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis, from 6 hours ago by Dow Jones
6 hours ago by Dow JonesIonis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome, from 6 hours ago by Dow Jones
6 hours ago by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ionis Pharmaceuticals Inc | 5.7B | -13.9x | --- |
Halozyme Therapeutics Inc | 5.8B | 18.8x | --- |
Apellis Pharmaceuticals Inc | 5.1B | -11.8x | --- |
Intra-Cellular Therapies Inc | 7.1B | -57.4x | --- |
CRISPR Therapeutics AG | 4.8B | -20.6x | --- |
ACADIA Pharmaceuticals Inc | 2.5B | -1,157.7x | --- |
Company Information
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Contact Information
- Headquarters
- 2855 Gazelle CourtCARLSBAD, CA, United States 92010
- Phone
- 760-931-9200
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Joseph Loscalzo
- Chief Executive Officer, Director
- Brett Monia
- Chief Financial Officer, Executive Vice President - Finance
- Elizabeth Hougen
- Executive Vice President, Chief Scientific Officer
- C. Frank Bennett
- Executive Vice President, Chief Business Officer
- Joseph Baroldi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.7B |
|---|---|
Revenue (TTM) | $776.6M |
Shares Outstanding | 146.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.35 |
EPS | $-2.67 |
Book Value | $2.68 |
P/E Ratio | -13.9x |
Price/Sales (TTM) | 7.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -45.47% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
